Authors
Latest:
Apretude PrEP Shows High Efficacy, Safety in Diverse StudiesNew data at CROI 2025 shows zero cases of HIV acquisition reported with Apretude (cabotegravir long-acting (CAB LA) for PrEP in varied clinical settings and populations in 2 implementation studies in the US and Brazil.
Latest:
Antimicrobial Stewardship: How to Extend a Solid HandshakeIn the latest column from SIDP, handshake stewardship prioritizes face-to-face communication between frontline providers to enable feedback to assess the appropriateness of prescribed antimicrobials.
Latest:
Expanding Tick-Borne Disease Trends in New JerseyEvelyn Wu, MD, reveals a rise in tick-borne diseases in New Jersey over the past two decades and correlations with the influence of warming climate conditions.
Latest:
Shifting to Shorter Courses of Antibiotic Therapy for Common Pediatric InfectionsIn the latest SIDP column, two clinicians provide information on recent studies and guidelines directed at antibiotic durations in this patient population.
Latest:
A Case of Hemophagocytic Lymphohistiocytosis Secondary to Cytomegalovirus InfectionThere have been sporadic cases Hemophagocytic Lymphohistiocytosis, associated with Cytomegalovirus Infection infection, suggesting that CMV may cause clinically significant disease beyond mononucleosis in immunocompetent individuals.
Latest:
Impact of Inpatient Pharmacist Review of Discharge AntibioticsA food for thought as an ambulatory antibiotic stewardship initiative.
Latest:
Evaluating the Efficacy of Paxlovid in High-Risk Patients with Pre-Existing ImmunityJohn McLaughlin, PhD, examines high-risk individuals with prior SARS-CoV-2 immunity and presents that Paxlovid reduces the risk of hospitalization, death, and severe symptoms, highlighting its ongoing value for high-risk patients in a post-peak pandemic landscape.
Latest:
Considerations for Antimicrobial Stewardship While Optimizing Therapy for a Patient With HIVHere is a case study involving a patient with the virus and the clinical approach in thinking about appropriate treatment while keeping stewardship in mind.
Latest:
Internal Tremors: Adding to the List of Long COVID SymptomsInternal tremors are a newly recognized and troubling symptom of Long COVID, experienced by over one-third of participants in a Yale-based study
Latest:
Discussing Outpatient COVID-19 TreatmentsHere is a look at some of the treatment alternatives, which can offer simpler logistics and cost considerations.
Latest:
The Role of Rifampin in Bone and Joint InfectionsIn the latest column from the Society of Infectious Diseases Pharmacists (SIDP), here is a discussion on the use of rifampin as an adjunctive antibiotic treatment for patients with diabetic foot osteomyelitis.
Latest:
Clarametyx Biosciences Initiates Phase 2a Trial for CMTX-101 in Cystic Fibrosis PatientsDavid Richards emphasized the therapy’s potential to enhance antibiotic effectiveness by targeting bacterial biofilms, a significant challenge in treatment.
Latest:
Updates and Controversies in Necrotizing Soft Tissue InfectionsChanges in microbiology and antimicrobial resistance patterns warrant reevaluation of our current therapies for this condition.
Latest:
Education and Advocacy in DC: The PLF C Diff Summit and Lobby DayThe Peggy Lillis Foundation's (PLF) CEO and Cofounder Christian John Lillis talks about these important events happening in the capital at the end of this month.
Latest:
Targeting C difficile with Oxygen-Based TherapyLarry Sutton, MD, PhD, discussed how oxygen affects C. difficile and provides anti-inflammatory effects in the gut, with potential applications for gastrointestinal diseases.
Latest:
Antibiotic Stewardship Programs Help Curb Superbug Threat by Leveraging DataThe OASIS platform will help outpatient facilities use prescribing data to improve patient care.
Latest:
A Personnel Problem: We Need More Antimicrobial Researchers, Infectious Disease CliniciansA decreasing number of researchers and open positions for infectious disease clinicians and limited residency matches are underlying issues that should be addressed to meet the needs around antimicrobial development and clinical care. Amesh Adalja, MD, FIDSA, discusses some of the challenges behind it.
Latest:
A Clinician’s Perspective on Rebyota for Recurrent C Diff TreatmentTimothy Ritter, MD, provides his insights on using the live biotherapeutic product and what both patients and clinicians can expect in terms of safety and efficacy.
Latest:
With Federal Offices Related to Fighting Infectious Disease Closing, Who Will Pick Up the Slack?Carl Schmid, executive director, HIV+Hepatitis Policy Institute, speaks to these closings.
Latest:
Sweeping Public Health Changes Create US and Global TurmoilWith the Trump administration’s plans to cease funding for Gavi, the Vaccine Alliance, as well as to reduce the US Department of Health and Human Services personnel, public health, both internationally and domestically, is going to be widely affected.
Latest:
ALLIANCE Study: B/F/TAF Achieves Sustained HIV and HBV SuppressionAnchalee Avihingsanon, MD, PhD presents results showing 95.4% HIV RNA suppression and 86.6% HBV DNA suppression after 48 weeks of B/F/TAF in HIV-HBV co-infected patients.
Latest:
How a Prodrug Approach May Aid In Antimalarial DevelopmentSesh Sundararaman, MD, PhD, discusses his findings and how this approach can be triggered to minimize undesirable treatment features and open the door to newer treatment possibilities.
Latest:
What's New In 2024: From the CLSI Subcommittee on Antimicrobial Susceptibility TestingThe Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing had its series of meetings to update breakpoints for a variety of classes of antimicrobials.
